Floatz logo

Immunoglobulin G1 [de-236-glycine,267-glutamic acid,de-C-terminal lysine], anti-(human tumor necrosis factor receptor TNFRSF9) (human-Mus musculus monoclonal LVGN6051 ?1-chain), disulfide with human-Mus musculus monoclonal LVGN6051 ?-chain, dimer

Metastatic Head and Neck Carcinoma

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

43 Active assets in the Metastatic Head and Neck Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB
Pembrolizumab
National Cancer Institute (NCI)
Phase 2BB
Nivolumab
National Cancer Institute (NCI)
Phase 2B
Tadalafil
University of California, San Diego
Phase 2B
Binimetinib
National Cancer Institute (NCI)
Phase 2CCC

View all 50 →

Same molecule, other indications

Immunoglobulin G1 [de-236-glycine,267-glutamic acid,de-C-terminal lysine], anti-(human tumor necrosis factor receptor TNFRSF9) (human-Mus musculus monoclonal LVGN6051 ?1-chain), disulfide with human-Mus musculus monoclonal LVGN6051 ?-chain, dimer is also rated in:

esophageal cancerDormant
CC
Indicative ·
43 / 100
View asset →
hepatocellular carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
Metastatic HPV Related Solid TumorsDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →